49 results about "Leucocythemia" patented technology

The invention relates to a double-screw micro-fluidic chip which comprises a chip inlet, a double-screw chip, an erythrocyte outlet, a leukocyte outlet, a fluid outlet and a cell filter membrane, wherein the chip is composed of two-screw-type channels, the two-screw-type channels are respectively punched along two tangent line directions of two mutually parallel chips to form two parallel reversed openings, one opening is connected with the chip inlet, and the other opening is respectively connected with the erythrocyte outlet, the leukocyte outlet and the fluid outlet. The double-screw micro-fluidic chip is capable of automatically feeding, dyeing and washing a sample, and automatically separating and enriching leukocytes in blood or / and pleural effusion of a patient suffering from leucocythemia at a high flux, thereby greatly improving diagnosis accuracy and precision; meanwhile, the double-screw micro-fluidic chip can be further used for separating in-vivo diseased leukocytes of the patient, and has a good treatment effect.

The invention relates to the field of medicinal chemistry, in particular to a heterocyclic anthracene ketone histone methyltransferase inhibitor and a preparation method and application of the heterocyclic anthracene ketone histone methyltransferase inhibitor. It is proved by pharmacology experiments that the compound has a good inhibiting effect on histone methyltransferase from the molecular level to the cell level, has good antiproliferative activity on tumor cell strains and has reasonable medicinal parameters, such as a proper dissociation constant (pKa), a lipid-aqueous partition coefficient (LogD, pH=7.4), water solubility and film transmittance. It is testified by research on pharmacokinetics that the compound is wide in distribution in a body of a rat, the plasma clearance can be within an acceptable range, and good bioavailability is achieved. The compound and the pharmaceutic preparation of the compound can be used for treating a series of diseases caused by disorder of enzyme activity of the histone methyltransferase, such as solid tumor, leucocythemia, malaria and neurodegenerative diseases.

The invention relates to a new application of furanodiene in pharmacy field, in particular to the application of the furanodiene in the preparation of medicines for treating the various malignant tumor diseases such as oophoroma, cervical carcinoma, gastric cancer, liver cancer, leucocythemia, lung cancer, oral carcinoma (epidermoid carcinoma), rectal adenocarcinoma, mammary cancer, malignant melanoma, colonic adenocarcinoma, nasopharyngeal carcinoma, carcinoma of prostate, etc. The invention also relates to the application of the furanodiene in the preparation of drugs for treating the diseases caused by herpesvirus, influenza virus and hepatitis B virus.

The invention relates to clinical application of a substituted aryl hydrazone compound and a derivative thereof serving as an anti-tumor necrosis factor inhibitor. A test result shows that the compound has a lower cytotoxicity in animal bodies, so the medical compound is expected to be used as an anti-TNF-alpha and TNF-beta inhibitor in the clinical application and is mainly used for treating some TNF related immunological diseases such as rheumatic arthritis, inflammatory bowel diseases, diabetes, hematosepsis, psoriasis, ankylosing spondylitis and some communicable diseases including HIV. A current TNF related research also shows that the medical compound can be used for treating clinical blood and solid tumor such as myelodysplastic syndrome, myelofibrosis, acute bone marrow cell leucocythemia, acute / chronic graft-versus-host reaction, ovarian cancer, nephrocyte cancer and the like.

The invention relates to novel homopiperazine acethydrazide derivatives as shown in formula I or formula II, signs in the formulas are defined as the specification. The invention also relates to a method for preparing the homopiperazine acethydrazide derivatives, and applications of the homopiperazine acethydrazide derivatives in preparation of medicaments for treating and / or preventing tumor and / or cancer, and the medicaments comprise medicinal compositions of the homopiperazine acethydrazide derivatives. The homopiperazine acethydrazide derivatives have effective tumor activity resistance, and can be particularly used for target treatment and / or lung cancer, leucocythemia and liver cancer.

The invention discloses a agent box to testing leucocyte susceptibility that includes two SNPs specificity primer in the 154th and the 170th of the upstream 5' adjust region SEQ ID NO: 1 that is testing PDCD5 gene, and restrain inscribe enzyme that is testing the SNPs site. The invention predicts the susceptibility of leucocyte by testing the site of SNP.

The invention discloses an anti-tumor compound extracted from a house lizard, as well as a preparation method of the anti-tumor compound extracted from the house lizard and application of the compound as antitumor drugs. In clinical application, the anti-tumor compound extracted from the house lizard can be dissolved with normal saline and then used in an injection way or can be prepared into preparation for oral use directly; the anti-tumor compound extracted from the house lizard can be used for the chemotherapy of gastric cancer, lung cancer, liver cancer, colon cancer, breast cancer, leucocythemia, genital system tumors, and other common malignant tumors, plays remarkable anti-tumor effect without bone marrow suppression or damage to important organs under conventional dosage; and in addition, since the anti-tumor compound extracted from the house lizard can increase T cellular immunity, the anti-tumor compound has good Aids resistance.

The invention belongs to the technical field of the natural drug, and discloses a chemical structure of a novel lycoris quinolone alkaloid extracted and separated from a lycoris plant atamasco. The compound is of a structure as shown in the formula on the right. The invention also discloses a preparation method and application of the compound in the field of medicine, in particular the application in preparation of anti-tumor drugs for treatment of leucocythemia and the like.

The invention relates to the field of medical technology. Ethyl 6-bromocoumarin-3-carboxylyl L-theanine, a novel synthetic compound, can inhibit the growth and invasion of cancer cells of human lung cancer, breast cancer, liver cancer, gastric cancer, colon cancer, prostatic cancer, pancreatic cancer, cervical cancer, lymphadenoma, leucocythemia, melanoma, and the like, and can remarkably inhibit the growth and metastasis of the tumors in a body, with an inhibiting effect exceeding the inhibiting effects of anti-cancer drugs. The mechanism of action involves the down regulation inhibition of the bonding of the receptors which are closely related to growth, invasion and metastasis of the tumors, signal transduction regulation and control proteins, the kinase level and a nuclear factor with DNA, and also upper regulation of factors such as cancer-inhibiting proteins and cell cycle inhibition proteins. The ethyl 6-bromocoumarin-3-carboxylyl L-theanine can directly inhibit the activity of histone deacetylase, the activity of histonemethylferase EZH2, and combination of a inflammatory factor NF-[Kabba]B and DNA. The activity of the ethyl 6-bromocoumarin-3-carboxylyl L-theanine exceeds the activity of the anti-cancer drugs. The invention provides new applications of the ethyl 6-bromocoumarin-3-carboxylyl L-theanine for prevention and treatment of diseases such as tumors, inflammation, heart and cerebral vessels and immunodeficiency.

The invention discloses novel sulfur-containing naphthalimide derivatives, and the preparation and uses thereof. The conjugated plane of naphthalimide derivatives of the invention is enlarged by incorporating 5-or 6-membered heteroaromatic ring and / or introducing S heteroatom, thus increasing the anti-tumor activity of naphthalimide. The compounds of the invention displays significant inhibiting activities to the proliferation of various tumor cells such as human lung cancer, gastric cancer, liver cancer, leucocythemia and the like. The inhibition of cell proliferation is dose-dependent.

The invention belongs to the fields of chemical industry and medicine, and relates to an application of chloranthus japonicus alcohol M in preparation of anti-neoplastic drugs. The invention provides the application of the chloranthus japonicus alcohol M in preparation of the anti-neoplastic drugs. Cancer cells comprise hepatoma carcinoma cells, cervical cancer cells, leucocythemia cells, and pancreatic cancer cells. The chloranthus japonicus alcohol M belongs to a natural product, is low in toxic side-effect, high in bioavailability, and stable in property, and has clinical use value. A small molecule compound of the chloranthus japonicus alcohol M is used as a novel anti-neoplastic drug or an auxiliary element of the novel anti-neoplastic drug to be developed, tumor suppression effect is obvious, green environmental protection is achieved, and a novel method and a novel means are supplied for tumour treatment and cure.

An application of the compound PS-341 in preparing the medicine for treating the M2-type acute medullary leukemia with the translocation of chromosome t (8;21) is disclosed. Its advantages are low dosage and moderate cost.

The invention relates to antitumor drugs, in particular to application of hellebores aglucon and derivatives thereof, and one or more of pharmaceutically acceptable salts. Experiments of in vitro cell biology show that the compounds can induce cycle arrest of various tumor cells of liver cancer, lung cancer, prostate glands cancer, leucocythemia and the like, remarkably inhibit the cell proliferation, and can be used for preparing drugs for inhibiting the growth of various tumor cells including the liver cancer.

The invention discloses an 8-cyclohexyl-2-fluoro-vidarabine, a preparation method thereof and an application of 8-cyclohexyl-2-fluoro-vidarabine to treatment of leucocythemia. By using a synthesis method disclosed by the invention, a heavy metal catalyst in the current synthesis method is avoided, the synthesis operation is simplified, heavy metal residues in 8-cyclohexyl-2-fluoro-vidarabine are avoided, and the preparation method is suitable for research and further large-scale preparation of drugs.

The invention discloses L-asparaginase as well as an encoding gene and application thereof. A protein disclosed by the invention is shown in the following formula (1) or (2): (1) the protein is a protein shown in SEQ ID No.2; and (2), the protein is a protein which is obtained through substitution and / or deficiency and / or addition of one or more amino acid residues on an amino acid sequence shown in SEQ ID No.2 and has the same function. The L-asparaginase disclosed by the invention is suitable for being used as a food additive applied to bakery products so that the production amount of acrylamide as a cancerogen in the product is reduced, and is also suitable for being used as a medicine applied to adjuvant therapy of leucocythemia.

An application of the compound MG-132 in preparing the medicines for treating the leukemia including M2-type acute medullary leukemia and chronic granulocytic leukemia is disclosed. Its advantages are low dosage and moderate cost.

The invention relates to the field of medical technology. Ethyl 6-chlorocoumarin-3-carboxylyl L-theanine, a novel synthetic compound, can inhibit the growth and invasion of cancer cells of human lung cancer, breast cancer, liver cancer, gastric cancer, colon cancer, prostatic cancer, pancreatic cancer, cervical cancer, lymphadenoma, leucocythemia, melanoma, and the like, and can remarkably inhibit the growth and metastasis of the tumors in a body, with an inhibiting effect exceeding the inhibiting effects of anti-cancer drugs. The mechanism of action involves the down regulation inhibition of the bonding of the receptors which are closely related to growth, invasion and metastasis of the tumors, signal transduction regulation and control proteins, the kinase level and a nuclear factor with DNA, and also upper regulation of factors such as cancer-inhibiting proteins and cell cycle inhibition proteins. The ethyl 6-chlorocoumarin-3-carboxylyl L-theanine can directly inhibit the activity of histone deacetylase, the activity of histonemethylferase EZH2, and combination of a inflammatory factor NF-[Kabba]B and DNA. The activity of the ethyl 6-chlorocoumarin-3-carboxylyl L-theanine exceeds the activity of clinical anti-cancer drugs. The invention provides new applications of the ethyl 6-chlorocoumarin-3-carboxylyl L-theanine in prevention and treatment of diseases such as tumors, inflammation, heart and cerebral vessels and immunodeficiency.

The invention discloses a diced bamboo shoot beancurd in wine, which is prepared from the following raw materials in parts by weight: 100-110 parts of soybean, 10-15 parts of sticky rice, 5-6 parts of cauliflower, 5-6 parts of broccoli, 3-4 parts of schisandra chinensis, 1-1.2 parts of polygala tenuifolia, 0.8-1 part of dutchmanspipe root, 5-6 parts of asparagus, 3-4 parts of red dates, 1-2 parts of fresh liquorice, 1-2 parts of radix paeoniae alba, 1-1.2 parts of ligusticum wallichii, 1-1.2 parts of radix notoginseng, 3-4 parts of purple sweet potato, 4-5 parts of winter bamboo shoots, 3-4 parts of tomato sauce, 4-5 parts of red wine, 1-2 parts of brine and 4-5 parts of nutrition additives. The diced bamboo shoot beancurd in wine, disclosed by the invention, is pleasant and delicious; the added bamboo shoot tender stem contains abundant protein, vitamins, mineral substances, trace elements required by a human body, and the like; bamboo shoots contain special asparagine which has a curative effect for cardiovascular diseases, edema, urocystitis and leucocythemia, and also have an anti-cancer effect. In addition, multiple Chinese medicinal herbs are added in a making process, and thus the diced bamboo shoot beancurd in wine has effects of tonifying the spleen and nourishing the stomach, promoting the circulation of Qi and relieving internal heat or fire, and invigorating the spleen and tonifying the Qi.

The invention relates to the field of medical technology. Ethyl coumarin-3-carboxylyl L-theanine, a novel synthetic compound, can inhibit the growth and invasion of cancer cells of human lung cancer, breast cancer, liver cancer, gastric cancer, colon cancer, prostatic cancer, pancreatic cancer, cervical cancer, lymphadenoma, leucocythemia, melanoma, and the like, and can remarkably inhibit the growth and metastasis of the tumors in a body, with an inhibiting effect exceeding the inhibiting effects of anti-cancer drugs. The mechanism of action involves the down regulation of receptors which are closely related to growth inhibition, invasion inhibition and metastasis inhibition of tumors, signal transduction regulation and control proteins, the kinase level and combination of a nuclear factor and DNA, and also upper regulation of factors such as cancer-inhibiting proteins and cell cycle inhibition proteins. The ethyl coumarin-3-carboxylyl L-theanine can directly inhibit the activity of histone deacetylase, the activity of histonemethylferase EZH2, and combination of a inflammatory factor NF-[Kabba]B and DNA. The activity of the ethyl coumarin-3-carboxylyl L-theanine exceeds the activity of the anti-cancer drugs. The invention provides new applications of the ethyl coumarin-3-carboxylyl L-theanine in prevention and treatment of disease such as tumors, inflammation, heart and cerebral vessels and immunodeficiency.

The invention relates to new application of dihydrocucurbitacin F-25-O-acetate in preparation of medicines for treating cancer. The invention also relates to the application of dihydrocucurbitacin F-25-O-acetate in preparation of medicines for treating leucocythemia.

The ASH2L expression would be specific decrease in the PMA exciting K562 differentiation process. And the DPY-30-like and WDR5 have no such alteration. Thus, ASH2L could be used as the alternate mark material to diagnose leukaemia. It constructs the N-end albumen of ASH2L and DPY-30-like full length albumen plasmid to transform to bacilluscoli expression corresponding albumen. It could be used to diagnose bacilluscoli diagnose.

The invention provides an apoptosis-related gene, the gene contains a base sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2. The invention also provides a carrier containing at least one target sequence of RNA interference for inhibiting the apoptosis-related gene. The invention also provides a cell which contains the carrier. The invention also provides a drug for curing leukemia, and the drug contains an effective amount of the RNA interference target sequence, or the carrier (containing the RNA interference target sequence) or the cell. The gene applies the RNA interference technique to inhibit PNAS-2, and has obvious effect to the treatment of leukemia.

The present invention provides recombinant inosculated albumen which can kill and wound leucocythemia cells. The albumen comprises human leucocyte interleukin IL3 segment and pseudomonas exotoxin. The human leucocyte interleukin IL3 segment is better to be located at the N-end of the inosculated albumen, and the pseudomonas exotoxin is better to be located at the C-end of the inosculated albumen. A bridge peptide is arranged between the human leucocyte interleukin IL3 segment and the pseudomonas exotoxin.

The invention relates to an application of a compound marsdenia tenacissima glycoside B which is extracted and separated from natural plant marsdenia tenacissima in the preparation of a drug for remedying tumour diseases including various malignant tumour diseases, such as ovary cancer, stomach cancer, liver cancer, leucocythemia, lung cancer, oral epidermoid carcinoma, rectal adenocarcinoma, breast cancer, malignant melanocarcinoma, colon adenocarcinoma, nasopharyngeal carcinoma, prostate cancer, etc. The invention also relates to a preparation technology of the marsdenia tenacissima glycoside B. After using water extraction and alcohol sedimentation, the invention uses an innovative chloroform extraction and aether sedimentation technology by chloroform extraction and also creatively adding aether, thereby reducing the content of impurity in extract obviously, and the marsdenia tenacissima glycoside B with high purity can be obtained just by silica gel column separation at a time. The method has high yield and simple operation, does not require a preparation type precision instrument of high performance liquid phase and other similar instruments and is closer to the requirement of the industrialized production.

An application of the compound PSI in preparing the medicines for treating the leukemia including M2-type acute medullary leukemia and chronic granulocytic leukemia is disclosed. Its advantages are low dosage and moderate cost.

The invention discloses a Chinese medicine pill for effectively treating arteriosclerosis, cerebral hemorrhage and sequela of cerebral thrombosis. The Chinese medicine pill is characterized by consisting of the following raw materials in proportion by weight: 25 to 35 grams of white ginseng, 25 to 35 grams of fritillaria hupehensis, 25 to 35 grams of radix scutellariae, 25 to 35 grams of rhizoma coptidis in Sichuan, 25 to 35 grams of fructus gardeniae, 25 to 35 grams of realgar, 25 to 35 grams of pearl, 15 to 25 grams of rhinoceros horn, 8 to 12 grams of borneol, 25 to 35 grams of radix curcumae, 25 to 35 grams of calamus, 15 to 25 grams of western bezoar, 8 to 15 grams of menthol, 25 to 35 grams of cinnabar, 800 to 1,000 grams of wild honey, and 8 to 12 grams of muskiness. The medicines are made into fine powder, and mixed with the honey to prepare pills with 4g per pill. The Chinese medicine pill also has good healing effects on patients suffering from viral coronary heart disease, viral hepatitis B and leucocythemia, and has cure rate of 85 percent.

The invention relates to a nitrogen contained alike derivate and medicine salt or solvolyte which can replace benzoic acid and which has the structure of formula (I) and cytotoxin activeness. The invention also relates to a preparation method for preparation formular(I) compound, the medicine compound and the medical functions. The compound of the invention has relative strong capability for restraining the growth of knub cell of liver cancer (BFL-7404) and leucocythemia (HL-60), and the compound can be used as anti-knub medicine anticipatorily.

A Chinese medicine for treating tumor and leukemia is prepared from 12 Chinese-medicinal materials including scorpion, liquorice root, aloe, pearl, etc. Its advantages are sure curative effect and low by-effect.

The invention discloses a leucocythemia bcr / abl fusion gene targeting micromolecule inhibitor. The compound is obtained through the reaction and salt forming of 2 Beta-(4'-methyl-1'- piperazine group)-3 Alpha-hydroxy-5 Alpha- steride -17-ketone and caffeic acid. The compound salt effectively suppresses the synthesis of mRNA of the bcr / abl fusion gene to inhibite the expression of BCR / ABL protein to inhibite the activity of protein-tyrosine kinase consequently to finally suppress the growth of leucocythemia cells. The compound salt is developed and is expected to be a bcr / abl fusion gene targeting therapeutic agent in the true sense. Therefore, the leucocythemia bcr / abl fusion gene targeting micromolecule inhibitor provides a brand new chemical entity for treating the CML and Ph positive (Ph+) chronic granulocytic leukemia and Ph positive (Ph<+>) acute lymphoblastic leukemia.

The invention provides a medicament for treating leucocythemia and other tumors, colonitis and fungal infection, namely a tryptanthrin injection emulsion, and a preparation process thereof, and belongs to the fields of pharmaceutical manufacture and clinical application. The tryptanthrin injection emulsion is characterized in that: tryptanthrin has the effects of killing and inhibiting tumor cells, transplanted tumors in animals, various fungi and bacteria, an effect of inhibiting inflammation, as well as regulation and other pharmacological activities to the immunity of a body. The tryptanthrin injection emulsion prepared by the tryptanthrin for treating leucocythemia and other tumors, colonitis and fungal infection can be used for treating the leucocythemia and other tumors, colonitis, fungal infection and other diseases. The tryptanthrin injection emulsion has the advantages of stable medicament, controllable quality, high bioavailability, small administration dosage, exact curative effect, low side response, rich raw material source and low production cost.